The role of the Notch pathway in the pathogenesis of systemic sclerosis: clinical implications

References

• Clements PJ, and Furst DE. Systemic sclerosis. 2nd ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2004. ISBN 978-0781737449 .
   Google Scholar
• Van PJT, Smith V, Haspeslagh M, et al. Histopathological cutaneous alterations in systemic sclerosis : a clinicopathological study. Arthritis Res Ther. 2011;13(1):R35.
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. NEJM. 2009;360(19):1989–2003.
   PubMed Web of Science ®Google Scholar
• Kavian N, Batteux F. Macro- and microvascular disease in systemic sclerosis. Vasc Pharmacol. 2015;71:16–23.
   PubMed Web of Science ®Google Scholar
• Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol. 2015;37(5):489–500.
   PubMed Web of Science ®Google Scholar
• Karassa FB, Ioannidis JBA. Mortality in systemic sclerosis. Clin Exp Rheumatol. 2008;26:S85–93.
   PubMed Web of Science ®Google Scholar
• Wei J, Bhattacharyya S, Tourtellotte WG, et al. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev. 2011;10(5):267–275.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatol (United Kingdom). 2012;51:1017–1026.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Inoue T, Gossler A, et al. Feedback loops comprising Dll1, Dll3 and Mesp2, and differential involvement of Psen1 are essential for rostrocaudal patterning of somites. Development 2003;130(18):4259–4268.
   PubMed Web of Science ®Google Scholar
• Lai EC. Notch signaling: control of cell communication and cell fate. Development 2004;131(5):965–973.
   PubMed Web of Science ®Google Scholar
• Chillakuri CR, Sheppard D, Lea SM, et al. Notch receptor-ligand binding and activation: insights from molecular studies. Semin Cell Dev Biol. 2012;23(4):421–428.
   PubMed Web of Science ®Google Scholar
• Gordon WR, Arnett KL, Blacklow SC. The molecular logic of Notch signaling–a structural and biochemical perspective. J Cell Sci. 2008;121(19):3109–3119.
   PubMed Web of Science ®Google Scholar
• Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194(3):237–255.
   PubMed Web of Science ®Google Scholar
• Ayaz F, Osborne BA. Non-canonical Notch signaling in cancer and immunity. Front Oncol. 2014;4:1–6.
   PubMedGoogle Scholar
• Andersen P, Uosaki H, Shenje L, et al. Non-canonical Notch signaling: emerging role and mechanism. Natl Institutes Heal. 2013;22:257–265.
   Google Scholar
• Layden MJ, Martindale MQ. Non-canonical Notch signaling represents an ancestral mechanism to regulate neural differentiation. Evodevo. 2014;5(1):30.
   PubMed Web of Science ®Google Scholar
• Jin S, Mutvei AP, Chivukula IV, et al. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene. 2013;32(41):4892–4902.
   PubMed Web of Science ®Google Scholar
• Kopan R. Notch signalling. 1st ed. San Diego, USA: Academic Press, Elsevier; 2010. ISBN 978-0-12-380914-8 .
   Google Scholar
• Rockey DC, Bell PD, Hill JA. Fibrosis — a common pathway to organ injury and failure. N Engl J Med. 2015;372(12):1138–1149.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Zhou Y, Gaggar A, et al. Fibrosis: ultimate and proximate causes. J Clin Invest. 2014;124(11):4673–4677.
   PubMed Web of Science ®Google Scholar
• Condorelli AG, El HM, and Zambruno G, et al. Notch - ing up knowledge on molecular mechanisms of skin fibrosis : focus on the multifaceted Notch signalling pathway. J Biomed Sci. 2021;28(36):1–17.
   PubMed Web of Science ®Google Scholar
• Zmorzy S, Styk W, Filip AA, et al. The significance of NOTCH pathway in the development of fibrosis in systemic sclerosis. Ann Dermatol. 2019;31(4):365–371.
   PubMed Web of Science ®Google Scholar
• Beyer C, Dees C, Distler JHW. Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Acta Dermatol Res. 2013;305(1):1–8.
   PubMed Web of Science ®Google Scholar
• Hu B, Phan SH. Notch in fibrosis and as a target of anti-fibrotic therapy. Pharmacol Res. 2016;108:57–64.
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JHW. Morphogen pathways in systemic sclerosis. Curr Rheumatol Rep. 2013;15(1):299.
   PubMed Web of Science ®Google Scholar
• Dees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis. 2011;70(7):1304–1310.
   PubMed Web of Science ®Google Scholar
• Parapuram SK, Shi-Wen X, Elliott C, et al. Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol. 2011;131(10):1996–2003.
   PubMed Web of Science ®Google Scholar
• Bertrand FE, McCubrey JA, Angus CW, et al. NOTCH and PTEN in prostate cancer. Adv Biol Regul. 2014;56:51–65.
   PubMedGoogle Scholar
• Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010;62(11):3477–3487.
   PubMed Web of Science ®Google Scholar
• Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–338.
   PubMed Web of Science ®Google Scholar
• Chen Y, Shi-wen X, and Eastwood M, et al. Contribution of activin receptor – like Kinase 5 (transforming growth factor β receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 2006;54(4):1309–1316.
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Thompson K, Khan K, et al. Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatol (United Kingdom). 2012;51:2146–2154.
   PubMed Web of Science ®Google Scholar
• Leask A. The hard problem: mechanotransduction perpetuates the myofibroblast phenotype in scleroderma fibrosis. Wound Repair Regen. 2021;29(4):582–587.
   PubMed Web of Science ®Google Scholar
• Totaro A, Castellan M, Di BD, et al. Crosstalk between YAP/TAZ and Notch signaling. Trends Cell Biol. 2018;28(7):560–573.
   PubMed Web of Science ®Google Scholar
• Zavadil J, Bitzer M, Liang D, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor- ␤. PNAS. 2001;98:6686–6691.
   PubMed Web of Science ®Google Scholar
• Blokzijl A, Dahlqvist C, Reissmann E, et al. Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J Cell Biol. 2003;163(4):723–728.
   PubMed Web of Science ®Google Scholar
• Sirin Y, Susztak K. The role of Notch in the kidney, development and beyond. J Pathol. 2012;226(2):394–403.
   PubMed Web of Science ®Google Scholar
• LaFoya B, Munroe JA, Mia MM, et al. Notch: a multi-functional integrating system of microenvironmental signals. Dev Biol. 2016;418(2):227–241.
   PubMed Web of Science ®Google Scholar
• Hu M, Wu C, and Qu S, et al. Notch signaling regulates col1a1 and col1a2 expression in airway fibroblasts. Exp Biol Med (Maywood). 2014; 239(12) :1589–96. DOI: https://doi.org/10.1177/1535370214538919.
   PubMed Web of Science ®Google Scholar
• Zhu C, Kim K, Wang X, et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med. 2018; 10(468) :1–14. DOI: https://doi.org/10.1126/scitranslmed.aat0344.
   Web of Science ®Google Scholar
• Syed F, Bayat A. Notch signaling pathway in keloid disease : enhanced fibroblast activity in a Jagged-1 peptide-dependent manner in lesional vs. extralesional fibroblasts. Wound Repair Regen. 2012;20(5):688–706.
   PubMed Web of Science ®Google Scholar
• Id SH, Park J, Qiu C, et al. Jagged1/Notch2 controls kidney fibrosis via Tfam -mediated metabolic reprogramming. PLoS Biol. 2018;16(9):e2005233.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Lebleu VS, Taduri G, Teng Y, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2014;19:1047–1053.
   Web of Science ®Google Scholar
• Xu H, Zaidi M, Struve J, et al. Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis. Am J Physiol Cell Physiol. 2011;300(3):C550–C556.
   PubMed Web of Science ®Google Scholar
• Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6:2–7.
   PubMed Web of Science ®Google Scholar
• Chang ACY, Fu Y, Garside VC, et al. Notch Initiates the Endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble Guanylyl Cyclase. Dev Cell. 2011;21(2):288–300.
   PubMed Web of Science ®Google Scholar
• Noseda M, McLean G, Niessen K, et al. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res. 2004;94(7):910–917.
   PubMed Web of Science ®Google Scholar
• Liu J, Dong F, Jeong J, et al. Constitutively active Notch1 signaling promotes endothelial-mesenchymal transition in a conditional transgenic mouse model. Int J Mol Med. 2014;34(3):669–676.
   PubMed Web of Science ®Google Scholar
• Jimenez SA. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol. 2013;2013:835948.
   PubMedGoogle Scholar
• Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med. 2013;3(1):1–19.
   Web of Science ®Google Scholar
• Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998;273(21):13313–13316.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Bohman S, Dixelius J, et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. Embo J. 2005;24(13):2342–2353.
   PubMed Web of Science ®Google Scholar
• Karamysheva A. Mechanisms of angiogenesis. Biochem. 2008;73:751–762.
   PubMed Web of Science ®Google Scholar
• Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007;104(9):3219–3224.
   PubMed Web of Science ®Google Scholar
• Liu Z, Shirakawa T, Li Y, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells : implications for modulating arteriogenesis and angiogenesis regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cel. Society 2003;23:14–25.
   Google Scholar
• Williams CK, Li JL, Murga M, et al. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006;107(3):931–939.
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Shawber CJ, Vorontchikhina M, et al. Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res. 2010;2(1):3.
   PubMedGoogle Scholar
• Harrington LS, Sainson RCA, Williams CK, et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res. 2008;75(2):144–154.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Archer C, Schaffer DV. Computational models of the Notch network elucidate mechanisms of context-dependent signaling. PLOS Comput Biol. 2009;5(5):e1000390.
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Shawber CJ, Sharma A, et al. Notch modulates VEGF action in endothelial cells by inducing matrix metalloprotease activity. Vasc Cell. 2011;3(1):2.
   PubMedGoogle Scholar
• Hellström M, Phng L-K, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445(7129):776–780.
   PubMed Web of Science ®Google Scholar
• Siekmann AF, Covassin L, Lawson ND. Modulation of VEGF signalling output by the Notch pathway. BioEssays 2008;30(4):303–313.
   PubMed Web of Science ®Google Scholar
• Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 2007;445(7129):781–784.
   PubMed Web of Science ®Google Scholar
• Sainson RCA, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 2008;11(1):41–51.
   PubMed Web of Science ®Google Scholar
• Yang K, Proweller A. Vascular smooth muscle notch signals regulate endothelial cell sensitivity to angiogenic stimulation. J Biol Chem. 2011;286(15):13741–13753.
   PubMed Web of Science ®Google Scholar
• Beets K, Huylebroeck D, Moya IM, et al. Robustness in angiogenesis: notch and BMP shaping waves. Trends Genet. 2013;29(3):140–149.
   PubMed Web of Science ®Google Scholar
• Li JL, Sainson RCA, Shi W, et al. Delta-like 4 Notch Ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67(23):11244–11253.
   PubMed Web of Science ®Google Scholar
• Patel NS, Li JL, Generali D, et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005;65:8690–8697.
   PubMed Web of Science ®Google Scholar
• Huang H. Pericyte-endothelial interactions in the retinal microvasculature. Int J Mol Sci. 2020;21(19):1–18.
   Web of Science ®Google Scholar
• Hellström M, Gerhardt H, Kalén M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;152:543–553.
   Web of Science ®Google Scholar
• Cutolo M, Smith V. State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative biomarker in rheumatology? Rheumatology (Oxford). 2013;52(11):1933–1940.
   PubMed Web of Science ®Google Scholar
• Paula F, Delgado Alves J. Notch signaling in microvascular endothelial cells is modulated by a serum factor in systemic sclerosis. 6th Syst Scler World Congr. Prague, Czech Republic; 2020. p. ID134.
   Google Scholar
• Vanderbeck A, Maillard I. Notch signaling at the crossroads of innate and adaptive immunity. J Leukocyte Biol. 2021;109(3):535–548.
   PubMed Web of Science ®Google Scholar
• Seguro Paula F, Ferreira IA, Amaral MC, et al. Systemic sclerosis-related changes on nailfold videocapillaroscopy in genetic and metabolic myopathies. Rheumatol (United Kingdom). 2016;55:1911–1912.
   PubMed Web of Science ®Google Scholar
• Kubo S, Todoroki Y, Nakayamada S, et al. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatol (United Kingdom). 2019;58:120–130.
   PubMed Web of Science ®Google Scholar
• Kontomanolis E, Panteliadou M, Giatromanolaki A, et al. Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis. Med Oncol. 2014;31(5). DOI:https://doi.org/10.1007/s12032-014-0945-0.
   Google Scholar
• D’Souza B, Miyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene. 2008;27(38):5148–5167.
   PubMed Web of Science ®Google Scholar
• Sheldon H, Heikamp E, Turley H, et al. New mechanism for Notch signaling to endothelium at a distance by delta-like 4 incorporation into exosomes. Blood 2010;116(13):2385–2394.
   PubMed Web of Science ®Google Scholar
• Wojcierowska-litwin M, Kowal M, and Michalska-jakubus M, et al. NOTCH3 T6746C and TP53 P72R polymorphisms are associated with the susceptibility to diffuse cutaneous systemic sclerosis. Biomed Res Int. 2020; 2020:1–9. DOI: https://doi.org/10.1155/2020/8465971. Article ID 8465971 .
   Web of Science ®Google Scholar
• Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 2011;63(5):1396–1404.
   PubMed Web of Science ®Google Scholar
• Crabtree JS, Osborne BA, and Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20(2): 125–44 . DOI: https://doi.org/10.1038/s41573-020-00091-3 .
   PubMed Web of Science ®Google Scholar
• Güner G, Lichtenthaler SF, Dzne D. The substrate repertoire of γ-secretase/presenilin. Semin Cell Dev Biol. 2020;105:27–42.
   PubMed Web of Science ®Google Scholar
• Riccio O, Van GME, Bezdek AC, et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 2008;9(4):377–383.
   PubMed Web of Science ®Google Scholar
• Moore G, Annett S, and McClements L, et al. Top Notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives. Cells 2020;9(6):1–46.
   Web of Science ®Google Scholar
• Samon JB, Castillo-martin M, Hadler M, et al. Preclinical analysis of the g -secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2012;11(7):1565–1576.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema ADR, Schellens JHM, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.
   PubMed Web of Science ®Google Scholar
• Christopoulos PF, Gjølberg TT, Krüger S, et al. Targeting the Notch signaling pathway in chronic inflammatory diseases. Front Immunol. 2021;12:1–22.
   Web of Science ®Google Scholar
• Ferrarotto R, Eckhardt G, Patnaik A, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018;29(7):1561–1568.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Wesolowski R, Baffa R, et al. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest New Drugs. 2020;38(1):120–130.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, LoRusso P, Strother RM, et al. A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin Cancer Res. 2015;21(12):2695–2703.
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Kotasek D, Markman B, et al. Phase IB trial of the anti-cancer stem cell DLL4-binding agent Demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC. Target Oncol. 2018;13(1):89–98.
   PubMed Web of Science ®Google Scholar
• Masiero M, Li D, Whiteman P, et al. Development of therapeutic anti-Jagged1 antibodies for cancer therapy. Mol Cancer Ther. 2019;18(11):2030–2042.
   PubMed Web of Science ®Google Scholar
• Lafkas D, Shelton A, Chiu C, et al. Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature 2015;528(7580):127–131.
   PubMed Web of Science ®Google Scholar
• Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. Embo J. 2001;20(13):3427–3436.
   PubMed Web of Science ®Google Scholar
• Distler A, Lang V, Del VT, et al. Combined inhibition of morphogen pathways demonstrates additive anti fi brotic effects and improved tolerability. Ann Rheum Dis. 2014;73(6):1264–1268.
   PubMed Web of Science ®Google Scholar
• Kubo S, Tanaka Y. Scleroderma in an ice-cream shop worker. Rheumatology (Oxford). 2019;58(6):1120–1121.
   PubMed Web of Science ®Google Scholar